Blog

FDA approves ReNeuron’s cryopreserved formulation of retinal stem cell therapy candidate – Healio

FDA approves ReNeuron's cryopreserved formulation of retinal stem cell therapy candidate
Healio
“We are delighted that the FDA has approved the use of the cryopreserved formulation of our hRPC retinal cell therapy candidate in our ongoing clinical development programs,” Olav Hellebø, CEO of ReNeuron, said in the release. “This is a further

2017-06-20 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.